We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+22.26%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$148M
AUM Growth
–
Cap. Flow
+$132M
Cap. Flow %
89.25%
Top 10 Hldgs %
53.27%
Holding
64
New
62
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$11.2M
2
PTX
Pernix Therapeutics Holdings, Inc.
PTX
+$5.76M
3
ALIM
Alimera Sciences
ALIM
+$5.72M
4
BEAT
BioTelemetry, Inc.
BEAT
+$4.15M
5
LMAT icon
LeMaitre Vascular
LMAT
+$3.31M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 47.62%
2 Consumer Discretionary 1.43%
3 Financials 1.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IWM icon
1
PUT
iShares Russell 2000 ETF
IWM
$81.5B
$27.5M 18.59%
+230,000
New +$26.3M
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$13.6M 9.18%
+1,632,720
New +$11.2M
QQQ icon
3
PUT
Invesco QQQ Trust
QQQ
$469B
$7.23M 4.88%
+70,000
New +$7.08M
ALIM
4
DELISTED
Alimera Sciences
ALIM
$5.86M 3.96%
+70,454
New +$5.72M
PTX
5
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$5.67M 3.83%
+60,408
New +$5.76M
BEAT
6
DELISTED
BioTelemetry, Inc.
BEAT
$4.85M 3.28%
+483,872
New +$4.15M
CEMP
7
CALL
DELISTED
Cempra, Inc.
CEMP
$3.87M 2.62%
+164,800
New +$2.46M
LMAT icon
8
LeMaitre Vascular
LMAT
$2.37B
$3.54M 2.39%
+463,000
New +$3.31M
LRMR icon
9
Larimar Therapeutics
LRMR
$413M
$3.09M 2.09%
+8,355
New +$2.15M
TTPH
10
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$2.97M 2.01%
+3,740
New +$2.01M
CTIC
11
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$2.9M 1.96%
+122,811
New +$2.84M
RRM
12
DELISTED
RR MEDIA LTD ORD SHS (ISR)
RRM
$2.89M 1.95%
+401,424
New +$2.91M
CORV
13
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$2.81M 1.9%
+303,477
New +$2.55M
VOLC
14
DELISTED
VOLCANO CORPORATION COM STK
VOLC
$2.74M 1.85%
+153,436
New +$1.84M
RXDX
15
DELISTED
Ignyta, Inc.
RXDX
$2.53M 1.71%
+369,360
New +$2.51M
VRTX icon
16
CALL
Vertex Pharmaceuticals
VRTX
$119B
$2.38M 1.61%
+20,000
New +$2.25M
RCPT
17
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$2.3M 1.55%
+18,768
New +$1.9M
ENTA icon
18
Enanta Pharmaceuticals
ENTA
$377M
$2.26M 1.53%
+44,528
New +$1.99M
HZNP
19
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$2.16M 1.46%
+167,491
New +$2.1M
VASC
20
DELISTED
Vascular Solutions Inc
VASC
$2.02M 1.37%
+74,494
New +$2.02M
OFIX icon
21
Orthofix Medical
OFIX
$496M
$2.02M 1.36%
+67,058
New +$1.97M
CERS icon
22
Cerus
CERS
$433M
$1.92M 1.3%
+308,282
New +$1.4M
IRIX icon
23
IRIDEX
IRIX
$14.4M
$1.8M 1.21%
+208,933
New +$1.66M
BBW icon
24
Build-A-Bear
BBW
$424M
$1.78M 1.21%
+88,740
New +$1.55M
EHTH icon
25
eHealth
EHTH
$43.8M
$1.73M 1.17%
+69,519
New +$1.69M
1
2 3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q4 2014 Portfolio in Review

Q4 2014 is the first quarter with a 13F filing on record for Acuta Capital Partners, which disclosed 64 positions worth $148M. Its ten largest holdings account for 53% of the portfolio.

Its largest position is Amicus Therapeutics: 1,632,720 shares worth $13.6M.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, followed by Consumer Discretionary and Financials.

  • Acuta Capital Partners's largest Q4 2014 buy was Amicus Therapeutics: 1,632,720 shares worth $13.6M.
  • Acuta Capital Partners's ten largest holdings make up 53% of its $148M portfolio in Q4 2014.
  • Acuta Capital Partners disclosed 64 positions in Q4 2014, its first 13F filing on record.

Based on Acuta Capital Partners's 13F filing for Q4 2014, filed 13 Feb 2015.